Literature DB >> 33503898

The Impact of Rubella Vaccine Introduction on Rubella Infection and Congenital Rubella Syndrome: A Systematic Review of Mathematical Modelling Studies.

Nkengafac Villyen Motaze1,2,3, Zinhle E Mthombothi4, Olatunji Adetokunboh2,4, C Marijn Hazelbag4, Enrique M Saldarriaga5, Lawrence Mbuagbaw2,3,6,7, Charles Shey Wiysonge2,3,8,9.   

Abstract

INTRODUCTION: Rubella vaccines have been used to prevent rubella and congenital rubella syndrome (CRS) in several World Health Organization (WHO) regions. Mathematical modelling studies have simulated introduction of rubella-containing vaccines (RCVs), and their results have been used to inform rubella introduction strategies in several countries. This systematic review aimed to synthesize the evidence from mathematical models regarding the impact of introducing RCVs.
METHODS: We registered the review in the international prospective register of systematic reviews (PROSPERO) with registration number CRD42020192638. Systematic review methods for classical epidemiological studies and reporting guidelines were followed as far as possible. A comprehensive search strategy was used to identify published and unpublished studies with no language restrictions. We included deterministic and stochastic models that simulated RCV introduction into the public sector vaccination schedule, with a time horizon of at least five years. Models focused only on estimating epidemiological parameters were excluded. Outcomes of interest were time to rubella and CRS elimination, trends in incidence of rubella and CRS, number of vaccinated individuals per CRS case averted, and cost-effectiveness of vaccine introduction strategies. The methodological quality of included studies was assessed using a modified risk of bias tool, and a qualitative narrative was provided, given that data synthesis was not feasible.
RESULTS: Seven studies were included from a total of 1393 records retrieved. The methodological quality was scored high for six studies and very high for one study. Quantitative data synthesis was not possible, because only one study reported point estimates and uncertainty intervals for the outcomes. All seven included studies presented trends in rubella incidence, six studies reported trends in CRS incidence, two studies reported the number vaccinated individuals per CRS case averted, and two studies reported an economic evaluation measure. Time to CRS elimination and time to rubella elimination were not reported by any of the included studies. Reported trends in CRS incidence showed elimination within five years of RCV introduction with scenarios involving mass vaccination of older children in addition to routine infant vaccination. CRS incidence was higher with RCV introduction than without RCV when public vaccine coverage was lower than 50% or only private sector vaccination was implemented. Although vaccination of children at a given age achieved slower declines in CRS incidence compared to mass campaigns targeting a wide age range, this approach resulted in the lowest number of vaccinated individuals per CRS case averted. CONCLUSION AND RECOMMENDATIONS: We were unable to conduct data synthesis of included studies due to discrepancies in outcome reporting. However, qualitative assessment of results of individual studies suggests that vaccination of infants should be combined with vaccination of older children to achieve rapid elimination of CRS. Better outcomes are obtained when rubella vaccination is introduced into public vaccination schedules at coverage figures of 80%, as recommended by WHO, or higher. Guidelines for reporting of outcomes in mathematical modelling studies and the conduct of systematic reviews of mathematical modelling studies are required.

Entities:  

Keywords:  congenital rubella syndrome; data synthesis; rubella; rubella-containing vaccines; systematic review

Year:  2021        PMID: 33503898      PMCID: PMC7912610          DOI: 10.3390/vaccines9020084

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  38 in total

1.  Simulation of mathematical models for public health problems.

Authors:  L Elveback; A Varma
Journal:  Public Health Rep       Date:  1965-12       Impact factor: 2.792

Review 2.  Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review.

Authors:  T Panagiotopoulos; I Antoniadou; E Valassi-Adam
Journal:  BMJ       Date:  1999-12-04

3.  Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.

Authors:  Kimberly M Thompson; Nima D Badizadegan
Journal:  Risk Anal       Date:  2017-05-31       Impact factor: 4.000

4.  Estimating the burden of congenital rubella syndrome in Costa Rica, 1996-2001.

Authors:  Gabriela Jiménez; María L Avila-Aguero; Ana Morice; Hazel Gutiérrez; Alejandra Soriano; Xiomara Badilla; Susan Reef; Carlos Castillo-Solórzano
Journal:  Pediatr Infect Dis J       Date:  2007-05       Impact factor: 2.129

Review 5.  Validation of population-based disease simulation models: a review of concepts and methods.

Authors:  Jacek A Kopec; Philippe Finès; Douglas G Manuel; David L Buckeridge; William M Flanagan; Jillian Oderkirk; Michal Abrahamowicz; Samuel Harper; Behnam Sharif; Anya Okhmatovskaia; Eric C Sayre; M Mushfiqur Rahman; Michael C Wolfson
Journal:  BMC Public Health       Date:  2010-11-18       Impact factor: 3.295

6.  Influence of demographically-realistic mortality schedules on vaccination strategies in age-structured models.

Authors:  Zhilan Feng; Yejuan Feng; John W Glasser
Journal:  Theor Popul Biol       Date:  2020-02-03       Impact factor: 1.514

7.  Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.

Authors:  Marc Brisson; Jane J Kim; Karen Canfell; Mélanie Drolet; Guillaume Gingras; Emily A Burger; Dave Martin; Kate T Simms; Élodie Bénard; Marie-Claude Boily; Stephen Sy; Catherine Regan; Adam Keane; Michael Caruana; Diep T N Nguyen; Megan A Smith; Jean-François Laprise; Mark Jit; Michel Alary; Freddie Bray; Elena Fidarova; Fayad Elsheikh; Paul J N Bloem; Nathalie Broutet; Raymond Hutubessy
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

8.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

9.  Balancing evidence and uncertainty when considering rubella vaccine introduction.

Authors:  Justin Lessler; C Jessica E Metcalf
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

Review 10.  Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines.

Authors:  Rebecca C Harris; Tom Sumner; Gwenan M Knight; Richard G White
Journal:  Hum Vaccin Immunother       Date:  2016-07-22       Impact factor: 3.452

View more
  3 in total

1.  Low Susceptibility of Rubella Virus in First-Trimester Trophoblast Cell Lines.

Authors:  Ngan Thi Kim Pham; Quang Duy Trinh; Kazuhide Takada; Shihoko Komine-Aizawa; Satoshi Hayakawa
Journal:  Viruses       Date:  2022-05-27       Impact factor: 5.818

2.  Epidemiological characteristic of rubella by age group during 12 years after the national introduction of rubella vaccine in Hangzhou, China.

Authors:  Jun Wang; Yuyang Xu; Xiaozhen Wang; Yan Liu; Xiaoping Zhang; Jian Du; Xinren Che; Wenwen Gu; Xuechao Zhang; Wei Jiang; Yi Wang
Journal:  Hum Vaccin Immunother       Date:  2022-03-28       Impact factor: 4.526

3.  A retrospective 5-year review of rubella in South Africa prior to the introduction of a rubella-containing vaccine.

Authors:  Heather Hong; Susan Malfeld; Sheilagh Smit; Lillian Makhathini; Mirriam Fortuin; Tshepo Motsamai; Dipolelo Tselana; Morubula Jack Manamela; Nkengafac Villyen Motaze; Genevie Ntshoe; Mercy Kamupira; Ester Khosa-Lesola; Sibongile Mokoena; Thulasizwe Buthelezi; Elizabeth Maseti; Melinda Suchard
Journal:  PLoS One       Date:  2022-05-05       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.